

Example Client, XYZ123 1234 Warde Road Ann Arbor MI 48108 **EXAMPLE, REPORT** WX0000003039 M 12/05/1988 34 Y

	-		-					
	I	Referral Test	•		_			
		Collected: 1	1/23/2021	1 08:36	Received:	11/23/2021	08:36	
<u>Test Name</u>	<u>R</u>	esult	Flag	Ref-Ranges	<u>s l</u>	<u>Jnits</u>	<u>Site</u>	
HIV-1 Genotype (RT	DL Integraço Inhik	nitore)						
HIV 1 Genotype	· · •	OT DETECTED					QCRL	
	i v	OTDETECTED						
The method used in this test is RT-PCR and sequencing of the HIV-1 polymerase gene.								
The phrases 'resistance predicted' and 'probable or emerging resistance' refer to the application of the interpretive rules. The FDA has not reviewed all of the interpretive rules used by the laboratory to predict drug resistance. FDA may not currently recognize some of the HIV gene mutations reported as predictive of drug resistance, but the laboratory considers these mutations to be associated with resistance to anti-viral drugs based on current clinical or scientific studies. The test has been validated pursuant to CLIA regulations and is not considered investigational or for research use only. Treatment decisions should be made in consideration of all relevant clinical and laboratory findings and the prescribing information for the drugs.								
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.								
33608 Ortega	stics Infectious Dise		terman	MD				
Value of Last Viral Load	45 (ISTIANO, CA 92075–20		cerman l	чт.,			QCRL	
Date Viral Load Collected	1 ²	1/11/2021					QCRL	
Raltegravir Resistance	N	OT PREDICTED					QCRL	
Elvitegravir Resistance		OT PREDICTED					QCRL	
Dolutegravir Resistance		OT PREDICTED					QCRL	
Bictegravir Resistance		OT PREDICTED					QCRL QCRL	
Cabotegravir Resistance NOT PREDICTED							QUKL	

The Quest Diagnostics September 2021 Interpretation Algorithm

LAB: L - LOW, H - HIGH, AB - ABNORMAL, C - CRITICAL, . - NOT TESTED

D123000000						
WX000003039						
Printed D&T: 11/30/23 14:59						

Ordered By: CLIENT CLIENT WX0000000001595 Kajal V. Sitwala, MD, PhD - Medical Director Form: MM RL1 PAGE 1 OF 2



Example Client, XYZ123 1234 Warde Road Ann Arbor MI 48108 **EXAMPLE, REPORT** WX0000003039 M 12/05/1988 34 Y

	Referral	Testing				
	Colle	ected: 11/23/2021	08:36	Received:	11/23/2021	08:36
<u>Test Name</u>	Result The method used in this test is RT-PCR and the HIV-1 integrase gene. The phrases 'rea and 'probable or emerging resistance' refe of the interpretive rules. The FDA has not interpretive rules used by the laboratory resistance. FDA may not currently recogniz gene mutations reported as predictive of a the laboratory considers these mutations a resistance to anti-viral drugs based on cu	sistance predi er to the appl t reviewed all to predict dr ze some of the drug resistanc to be associat	cted' ication of the cug e HIV ce, but ced with	<u>s</u> <u>U</u>	<u>nits</u>	<u>Site</u>
	This test was developed and its analytical characteristics have been determined by Qu It has not been cleared or approved by FDD been validated pursuant to the CLIA regula for clinical purposes. For more information on this test, go to: http://education.questdiagnostics.com/faq,	uest Diagnosti A. This assay ations and is /FAQ135	has used			
	<pre>(This link is being provided for informat: purposes only.) Test Performed at: Quest Diagnostics Infectious Disease, Inc 33608 Ortega Highway San Juan Capistrano, CA 92675-2042 H</pre>	J Batterman M		1/23/2021	08:39 H\	/GII
	QCRL: QUEST DIAGNOSTI					ming Site: CA 92675

LAB: L - LOW, H - HIGH, AB - ABNORMAL, C - CRITICAL, . - NOT TESTED

Ordered By: CLIENT CLIENT WX0000000001595